Abstract
The approval of aducanumab for the treatment of Alzheimer’s disease has been met with significant public concern. Projections of annual cost across United States Medicare beneficiaries are in the tens of billions of dollars. Here, we performed an electronic health record review of Veterans Affairs beneficiaries, identifying 151,921 individuals (1.7%) with diagnosis codes for Alzheimer’s disease. We estimate that treatment for this cohort will cost in excess of $4 billion annually with further expenditures for associated screening, consultations, imaging, and therapeutic monitoring. The magnitude of projected expenditures necessitates early assessment of drug cost effectiveness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No specific funding was received for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Veterans Affairs institutional review board (1583221-6).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
VA DISCLAIMER. The views expressed in this paper are those of the authors and do not necessarily represent the views of the United States Department of Veterans Affairs, the United States Government, or the affiliated academic institutions.
Data Availability
The data presented are not publicly available.
